Analysis – Page 191 – Goldea Capital

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

Written by Customer Service on April 6, 2026. Posted in Public Companies.

CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Wednesday, April 29, 2026, at 8:00 a.m. ET to report its first quarter 2026 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event. About Agios: Fueled by Connections to Transform Rare Diseases™At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build...

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital

Written by Customer Service on April 6, 2026. Posted in Public Companies.

– Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment – – Strategic financing to accelerate development of earlier-stage gene therapy programs with three additional programs entering clinical testing over the next year – – Current cash of approximately $100 million now extends cash runway into 2029, through expected completion of OPGx-LCA5 and OPGx-BEST1 pivotal studies, potential approvals, and the prospect to receive priority review vouchers – – Three-month topline results from full Cohort 1 of Phase 1/2 trial with OPGx-BEST1 remain on track for mid-2026 – RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics”, “Opus”, or the “Company”),...

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application

Written by Customer Service on April 6, 2026. Posted in Public Companies.

NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx’s preservative-free ketamine product. Labeling remains subject to final supervisory review. NRx previously received a preliminary determination of bioequivalence for this product. The Company continues to anticipate a decision on approval under the Generic Drug User Fee Act (GDUFA) in Summer 2026.WILMINGTON, Del., April 06, 2026 (GLOBE NEWSWIRE) — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has received a letter from the Labeling Program of the FDA Office of Generic Drugs whose only comments were limited to minor formatting changes to the proposed label for the Company’s preservative-free ketamine product. The Company expects to submit the...

NFI schedules release of first quarter 2026 financial results and provides details about Annual and Special Meeting of Shareholders

Written by Customer Service on April 6, 2026. Posted in Public Companies.

WINNIPEG, Manitoba, April 06, 2026 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI or the Company) a leading manufacturer of buses and coaches and a provider of comprehensive aftermarket parts and service solutions, today announced the release date of its first quarter of 2026 (Q1 2026) financial results and notes that the Company’s Board of Directors (Board) has set the date for its Annual and Special Meeting of Shareholders for May 8, 2026 at 11:00 a.m. Eastern Time (ET). First Quarter 2026 Results Release NFI intends to release its Q1 2026 financial results on Thursday, May 7, 2026, after market close with a conference call and webcast to discuss the results on Friday, May 8, 2026, at 8:30 a.m. ET. For attendees who wish to join by webcast, registration is not required; the event can be accessed at...

Arkansas Otolaryngology Center Selects CareCloud to Power Next-Level Practice Management and Revenue Optimization with AI-Enabled Solutions

Written by Customer Service on April 6, 2026. Posted in Public Companies.

SOMERSET, N.J., April 06, 2026 (GLOBE NEWSWIRE) — CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leading provider of healthcare technology and AI-enabled revenue cycle management (“RCM”) solutions, today announced a new partnership with Arkansas Otolaryngology Center, P.A., one of the region’s most respected Ear, Nose, Throat, Allergy, and Sleep practices. Based in Little Rock, the multi-location practice has selected CareCloud’s AI-powered practice management and revenue cycle management solutions to streamline operations, accelerate revenue capture, and elevate the patient experience across Arkansas. “We are thrilled to partner with CareCloud as we enhance our practice management system and RCM operations,” said Jelinda Scott, Chief Administrative Officer of Arkansas Otolaryngology Center. “Their technology...

Sharps Technology Reports 2025 Year-End Results and Highlights Continued Execution of Solana Treasury Strategy

Written by Customer Service on April 6, 2026. Posted in Earnings Releases And Operating Results.

Over 2 Million SOL Held with Approximately 95% Staked at ~7% Gross Annualized Yield Total Assets of $269.1 Million, Up from $7.3 Million at Year-End 2024 Expanded Solana Ecosystem Partnerships Including Coinbase, Crypto.com, BitGo, and JupiterNEW YORK, April 06, 2026 (GLOBE NEWSWIRE) — Sharps Technology, Inc. (“Sharps” or the “Company”), a medical device sales and distribution company that has adopted a Solana-based digital asset treasury strategy, has announced financial results for the year ended December 31, 2025, and provided an update on the continued execution of its treasury and infrastructure strategy. The Company entered 2025 as a capital-constrained medical device manufacturer and exited 2025 with what management believes is the strongest financial and strategic platform in the Company’s history. In a matter of months,...

Amplify ETFs Declares March Income Distributions for Crypto Monthly Option Income ETFs

Written by Customer Service on April 6, 2026. Posted in Dividend Reports And Estimates.

Distribution rates for BAGY 41.80%, BITY 27.90%, EHY 50.52%, ETTY 36.10%, SOLM 38.58%, XRPM 36.82% CHICAGO, April 06, 2026 (GLOBE NEWSWIRE) — Amplify ETFs announces March income distribution rates for its digital asset suite of option income ETFs: BAGY, BITY, EHY, ETTY, SOLM, and XRPM.ETF Name Ticker DistributionRate1 Amount per Share DistributionFrequency 30-DaySEC Yield1Amplify Bitcoin Max Income Covered Call ETF BAGY 41.80% $0.96966 Monthly 0.98%Amplify Bitcoin 2% Monthly Option Income ETF BITY 27.90% $0.69480 Monthly 0.66%Amplify Ethereum Max Income Covered Call ETF EHY 50.52% $0.44375 Monthly 2.69%Amplify Ethereum 3% Monthly Option Income ETF ETTY 36.10% $0.32790 Monthly 2.18%Amplify Solana 3% Monthly Option Income ETF SOLM 38.58% $0.35010 Monthly 5.66%Amplify XRP 3% Monthly Option Income ETF XRPM 36.82% $0.42900 Monthly 1.54%There...

Kraig Biocraft Laboratories Shatters Production Record, Delivering Over 1.3 Metric Tons of Spider Silk Cocoons in a Single Month, A 5X Increase Over Previous High

Written by Customer Service on April 6, 2026. Posted in Public Companies.

Record-breaking output validates aggressive scale-up strategy as Company accelerates toward 10 metric tons per month ANN ARBOR, Mich., April 06, 2026 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that it has produced more than 1.3 metric tons of recombinant spider silk cocoons in a single month. This is a new world record and shatters the Company’s previous production record by a factor of five. Today marks a pivotal step forward in the transition of spider silk from laboratory innovation to an industrial-scale material platform.When Kraig Labs unveiled its 2026 production plan in February, the Company committed to an aggressive timeline to scale spider silk...

urban-gro, Inc. Outlines Strategy Targeting Global T20 Cricket Market and Near-Term Execution Milestones

Written by Customer Service on April 6, 2026. Posted in Public Companies.

LAFAYETTE, Colo., April 06, 2026 (GLOBE NEWSWIRE) — urban-gro, Inc. (Nasdaq: UGRO) (“urban-gro” or the “Company”), today furnished an investor presentation via a Current Report on Form 8-K, outlining elements of its strategic focus on opportunities within the global T20 cricket ecosystem, a market characterized by significant media rights activity, franchise development, and growing global audience engagement. Following the recent strategic integration of urban-gro with Flash Sports & Media, Inc. (Flash) and Innovative Production Group, Inc. (IPG), the Company has established a vertically integrated platform designed to originate, control, and monetize premium sports and entertainment IP at scale. Defined Catalyst Stack with Near-Term Execution Timeline: Catalyst 1 – Market Entry (Immediate): Targeted...

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Written by Customer Service on April 6, 2026. Posted in Public Companies.

NEW HAVEN, Conn., April 06, 2026 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD) today announced that on April 1, 2026, Invivyd granted 16 newly hired non-executive employees options to purchase an aggregate of 1,083,750 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan. The options have a per share exercise price of $1.33, representing the closing price of Invivyd’s common stock on the grant date. Each option vests over four years, with 25% of the shares subject to such option vesting on the first anniversary of the employee’s start date and the remaining shares vesting in equal monthly installments thereafter, in each case, subject to the...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals